FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m.

新泽西州弗洛勒姆公园，2024年5月3日（环球通讯社）--BeyondSpring Inc.（纳斯达克：BYSI）（“BeyondSpring”或“公司”），一家专注于开发创新癌症疗法的临床阶段全球生物制药公司，今天宣布将于2024年5月15日星期三上午10:。

ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), and Steven Lin, M.D. (MD Anderson Cancer Center), who will discuss below topics: Plinabulin history and development strategy for cancerPlinabulin’s immunomodulatory activity as a DC maturation agentUnmet needs after immune-checkpoint-inhibitor failure Also featured will be a management discussion on technology platform and pipeline updates of SEED Therapeutics, BeyondSpring’s majority-owned molecular glue subsidiary.

等。电话会议和网络研讨会将由关键意见领袖（KOL）Trevor M.Feinstein，M.D.（皮埃蒙特癌症研究所），Alberto Chiappori，M.D.（莫菲特癌症中心）和Steven Lin，M.D.（安德森癌症中心），他们将讨论以下主题：Plinabulin作为DC成熟剂的免疫调节活性的历史和发展策略免疫检查点抑制剂失败后的需求也将是关于BeyondSpring拥有多数股权的分子胶子公司SEED Therapeutics的技术平台和管道更新的管理讨论。

The dial in numbers for the conference call are 1-877-407-0779 (U.S.) or 1-201-389-0914 (international). To register for the webinar, please click here. An archived replay of the webinar will be available following the presentation on BeyondSpring’s website www.beyondspringpharma.com under “Events and Presentations” in the Investors section.

电话会议的拨入号码是1-877-407-0779（美国）或1-201-389-0914（国际）。要注册网络研讨会，请单击此处。在BeyondSpring的网站www.beyondspringpharma.com的投资者部分的“事件和演示”下进行演示后，将提供网络研讨会的存档重播。

Trevor M. Feinstein, M.D.Dr. Feinstein is board certified in medical oncology and hematology. He joined Piedmont Cancer Institute in 2011 and is the Director of Research at Piedmont Fayette Hospital. Dr. Feinstein is actively involved in clinical trials focused on improved therapies for various cancers.

Trevor M.Feinstein医学博士Feinstein拥有医学肿瘤学和血液学的董事会认证。他于2011年加入皮埃蒙特癌症研究所，是皮埃蒙特法耶特医院的研究主任。范斯坦博士积极参与旨在改进各种癌症治疗方法的临床试验。

He is a member of Georgia CORE’s res.

他是乔治亚核心研究所的成员。